Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: A research synthesis

Journal of Viral Hepatitis

Volumn 14, Issue 4, 2007, Pages 239-248

  Shire, N J ^a   Welge, J A ^a,b   Sherman, K E ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatitis C virus human immunodeficiency virus coinfection; Hepatitis treatment response; Meta analysis; Pegylated interferon

Indexed keywords

ANTIRETROVIRUS AGENT; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; BAYES THEOREM; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS LOAD;

ANTIVIRAL AGENTS; BAYES THEOREM; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN;

EID: 33947422997     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00824.x     Document Type: Article

References (34)

1. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38(2): 575-577.
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34(6): 831-837.
3. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32(3): 492-497.
4. Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33(4): 562-569.
5. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975-982.
6. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958-965.
7. Chung RT, Andersen J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351(5): 451-459.
8. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351(5): 438-450.
9. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292(23): 2839-2848.
10. Perez-Olmeda M, Nunez M, Romero M et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17(7): 1023-1028.
11. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18(13): F27-F36.
12. Moreno L, Quereda C, Moreno A et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18(1): 67-73.
13. Cargnel A, Angeli E, Mainini A et al. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 2005; 10(2): 309-317.
14. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med 2002; 21(11): 1601-1623.
15. Thompson SG, Warn DE, Turner RM. Bayesian methods for analysis of binary outcome data in cluster randomized trials on the absolute risk scale. Stat Med 2004; 23(3): 389-410.
16. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23(11): 1663-1682.
17. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21(11): 1559-1573.
18. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Methods in health service research. An introduction to Bayesian methods in health technology assessment. BMJ 1999; 319(7208): 508-512.
19. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001; 10(4): 277-303.
20. Gelman A, Rubin D. Inference from iterative simulation using multiple sequences (with discussion). Stat Sci 1992; 7: 457-511.
21. Harbord M, Higgins JPT. Meta-analysis regression revisited. Stata J 2006; (in press).
22. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-1558.
23. Sterne JA, Bradburn MJ, Egger M. Meta-analysis in Stata. In: Egger M, Smith G, Altman D, eds. Systematic Reviews in Health Care, 2nd edn. Oxford, UK: BMJ, 2001: 347-68.
24. Nunez M, Camino N, Ramos B et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther 2005; 10(5): 657-662.
25. Soriano V, Nunez M, Sanchez-Conde M et al. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4. Antivir Ther 2005; 10(1): 167-170.
26. Legrand-Abravanel F, Nicot F, Boulestin A et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005; 77(1): 66-69.
27. Khalili M, Bernstein D, Lentz E, Barylski C, Hoffman-Terry M. Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial. Dig Dis Sci 2005; 50(6): 1148-1155.
28. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med 2003; 22(17): 2693-2710.
29. Lai R, Crevier L, Thabane L. Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005; 14(7): 1784-1790.
30. Tine F, Attanasio M, Russo F, Pagliaro L. A decade of trials of interferon-alpha for chronic hepatitis C. A meta-regression analysis. Contemp Clin Trials 2005; 26(2): 179-210.
31. Soriano V, Garcia-Samaniego J, Bravo R et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23(3): 585-591.
32. Landau A, Batisse D, Piketty C et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001; 15(16): 2149-2155.
33. Sherman KE, Shire NJ, Rouster SD et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005; 128(2): 313-327.
34. Torriani FJ, Ribeiro RM, Gilbert TL et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003; 188(10): 1498-1507.